Payment overview · 2025
General Payments
$487.92
34 reported records · 8 companies
Healthcare provider profile · identity verified
Kayla Walker, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · HOPKINSVILLE, KY · NPI 1881103448
Verified facts
What the public records show
CMS Open Payments records show Kayla Walker, APRN received $487.92 in general payments during 2025 across 34 reported records.
ABBVIE INC. accounted for 45.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $221.41 | 45.4% | 22 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $107.05 | 21.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.79 | 9.8% | 3 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $28.17 | 5.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.38 | 5.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.59 | 4.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.41 | 3.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.12 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $487.92 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $199.72 | 21 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $107.05 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $28.17 | 1 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 83 |
| Atorvastatin Calcium | Atorvastatin Calcium | 254 | 70 |
| Losartan Potassium | Losartan Potassium | 226 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 222 | 72 |
| Lisinopril | Lisinopril | 222 | 58 |
| Simvastatin | Simvastatin | 179 | 41 |
| Prednisone | Prednisone | 177 | 118 |
| Furosemide | Furosemide | 172 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 45 |
| Montelukast Sodium | Montelukast Sodium | 165 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 43 |
| Omeprazole | Omeprazole | 160 | 47 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 111 | 28 |
| Fluconazole | Fluconazole | 107 | 54 |
| Gabapentin | Gabapentin | 99 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 23 |
| Carvedilol | Carvedilol | 96 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 25 |
| Sertraline Hcl | Sertraline Hcl | 95 | 28 |
| Famotidine | Famotidine | 91 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 23 |
| Trazodone Hcl | Trazodone Hcl | 85 | 27 |
| Estradiol | Estradiol | 83 | 20 |
| Potassium Chloride | Potassium Chloride | 81 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 20 |
| Alendronate Sodium | Alendronate Sodium | 79 | 16 |
| Amoxicillin | Amoxicillin | 79 | 59 |
| Pravastatin Sodium | Pravastatin Sodium | 78 | 19 |
| Celecoxib | Celecoxib | 77 | 19 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 74 | 60 |
| Metformin Hcl | Metformin Hcl | 71 | 20 |
| Ozempic | Semaglutide | 70 | 18 |
| Spironolactone | Spironolactone | 70 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 25 |
| Alprazolam | Alprazolam | 65 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 64 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | 14 |
| Synthroid | Levothyroxine Sodium | 57 | 15 |
| Bupropion Xl | Bupropion Hcl | 55 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 36 |
| Allopurinol | Allopurinol | 54 | 13 |
| Ondansetron Odt | Ondansetron | 53 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 52 | 42 |
| Eliquis | Apixaban | 51 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 12 |
| Jardiance | Empagliflozin | 47 | 11 |
| Valacyclovir | Valacyclovir Hcl | 47 | 22 |
| Azithromycin | Azithromycin | 46 | 40 |
| Risperidone | Risperidone | 45 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 41 | 22 |
| Glipizide Er | Glipizide | 40 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Methotrexate | Methotrexate Sodium | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 15 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Nystatin | Nystatin | 27 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | 11 |
| Glipizide | Glipizide | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 20 |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Metronidazole | Metronidazole | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Indapamide | Indapamide | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $487.92 · 34 records | ABBVIE INC. | AIRSUPRA, Axonics, CAPLYTA, Dexcom G6 Transmitter, ImmunoCAP, MOUNJARO, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error